目的 探讨急性心肌梗死溶栓治疗与普通治疗后血清心肌酶学指标的变化情况.方法 检测并分析接受溶栓治疗(实验组)或普通治疗(对照组)急性心肌梗死患者血清肌酸激酶(CK)、肌酸激酶同工酶MB(CK-MB)水平.结果 实验组与对照组治疗前血清CK、CK-MB检测结果差异无统计学意义(P＞0.05),治疗12 h后检测结果差异有统计学意义(P＜0.05).实验组和对照组治疗12 h后冠状动脉再通率、心力衰竭发病率、心律失常发病率及住院期间病死率差异有统计学意义(P＜0.05).结论 尿激酶溶栓治疗有利于急性心肌梗死患者实现冠状动脉再通,能够更有效地预防急性心肌梗死病情恶化,其疗效优于一般治疗,值得在临床推广.%To explore the changes of cardiac muscle enzymology indexes between patients with AMI and being trea ted with thrombolytic or common therapy. Methods CK and CK MB of patients with AMI and being treated with thrombolytic (experimental group) and common (control group) therapy were detected and analyzed. Results There were statistical differences of CK and CK MB of experimental and control group,after being treated for 12 h(P＜0.05). The differences of rates of coronary artery recanalization, heart failure,arrhythmia and case fatality during hospital stay were also significant between the two groups(P ＜0.05). Conclusion The urokinase thrombolytic therapy is helpful for the coronary artery recanalization and the prevention of the aggravation in patients with AMI.
展开▼
